The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study

Basit Öğe Kaydı
dc.contributor.authorTombak, Anıl
dc.contributor.authorUçar, Mehmet Ali
dc.contributor.authorAkdeniz, Aydan
dc.contributor.authorTiftik, Eyüp Naci
dc.contributor.authorŞahin, Deniz Gören
dc.contributor.authorAkay, Olga Meltem
dc.contributor.authorSungur, Mehmet Ali
dc.date.accessioned2020-04-30T23:34:26Z
dc.date.available2020-04-30T23:34:26Z
dc.date.issued2016
dc.departmentDÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.descriptionKaynar, Leylagul/0000-0002-2035-9462; GURKAN, EMEL/0000-0002-3060-4054; Sahin, Fahri/0000-0001-9315-8891en_US
dc.descriptionWOS: 000392282500002en_US
dc.descriptionPubMed: 27095141en_US
dc.description.abstractObjective: In this study, we aimed to investigate the efficacy and safety of azacitidine (AZA) in elderly patients with acute myeloid leukemia (AML), including patients with >30% bone marrow (BM) blasts. Materials and Methods: In this retrospective multicenter study, 130 patients of >= 60 years old who were ineligible for intensive chemotherapy or had progressed despite conventional treatment were included. Results: The median age was 73 years and 61.5% of patients had >30% BM blasts. Patients received AZA for a median of four cycles (range: 1-21). Initial overall response [including complete remission (CR)/CR with incomplete recovery/partial remission] was 36.2%. Hematologic improvement (HI) of any kind was documented in 37.7% of all patients. HI was also documented in 27.1% of patients who were unresponsive to treatment. Median overall survival (OS) was 18 months for responders and 12 months for nonresponders (p=0.005). In the unresponsive patient group, any HI improved OS compared to patients without any HI (median OS was 14 months versus 10 months, p=0.068). Eastern Cooperative Oncology Group performance status of <2, increasing number of AZA cycles (>= 5 courses), and any HI predicted better OS. Age, AML type, and BM blast percentage had no impact. Conclusion: We conclude that AZA is effective and well tolerated in elderly comorbid AML patients, irrespective of BM blast count, and HI should be considered a sufficient response to continue treatment with AZA.en_US
dc.identifier.doi10.4274/tjh.2015.0203en_US
dc.identifier.endpage280en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue4en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage273en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.2015.0203
dc.identifier.urihttps://hdl.handle.net/20.500.12684/5162
dc.identifier.volume33en_US
dc.identifier.wosWOS:000392282500002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal Of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAzacitidineen_US
dc.subjectAcute myeloid leukemiaen_US
dc.subjectElderlyen_US
dc.subjectBone marrow blastsen_US
dc.subjectPrognostic factorsen_US
dc.subjectOverall survivalen_US
dc.titleThe Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
5162.pdf
Boyut:
250.44 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu